glp3.wiki
Investigational · not FDA approved

Editorially reviewed · Last updated September 8, 2026 · How we review

What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH

Part of Weight Loss Drug Profiles: Every GLP-1 and GLP3 Agonist.

What Is Survodutide? The Dual GLP-1/Glucagon Agonist for Weight Loss and MASH

Survodutide (development code: BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim in partnership with Zealand Pharma. It is a once-weekly subcutaneous injection that activates two hormone receptors simultaneously: GLP-1 (for appetite suppression) and glucagon (for increased energy expenditure and direct effects on liver fat).
The Phase 3 SYNCHRONIZE-1 trial enrolled 725 adults with overweight or obesity without diabetes. At 76 weeks, average weight loss was 12.2% with 3.6 mg and 13.0% with 6.0 mg, versus 5.4% with placebo, in the analysis accounting for treatment discontinuation.

Survodutide remains investigational. Obesity Phase 3 results are now published; the MASH development program is a separate assessment of liver disease.

How Survodutide Works

Dual GLP-1/Glucagon Mechanism

Unlike most next-generation obesity drugs that pair GLP-1 with GIP (as tirzepatide does), survodutide pairs GLP-1 with glucagon. This is a fundamentally different approach. The two receptor components work through complementary mechanisms:
GLP-1 receptor agonism provides the effects familiar from drugs like semaglutide and tirzepatide:
  • Reduces appetite by acting on GLP-1 receptors in the hypothalamus
  • Slows gastric emptying, prolonging the feeling of fullness after meals
  • Stimulates insulin secretion in a glucose-dependent manner
  • Suppresses post-meal glucagon from the pancreas
Glucagon receptor agonism adds a distinct metabolic layer that other incretin drugs do not provide:
  • Increases energy expenditure — glucagon stimulates thermogenesis and raises resting metabolic rate, meaning the body burns more calories even at rest
  • Promotes hepatic fat oxidation — glucagon acts directly on liver cells to increase fat burning, which is why survodutide has particular relevance for MASH
  • Stimulates hepatic glycogenolysis — glucagon triggers the liver to break down glycogen stores

Why Glucagon Instead of GIP?

The addition of glucagon is counterintuitive at first glance. Glucagon raises blood sugar — the opposite of what GLP-1 does. In diabetic patients, excess glucagon is considered part of the problem.

The rationale is that the GLP-1 component counterbalances the glucose-raising effect of glucagon, while the glucagon component adds metabolic benefits that GLP-1 alone cannot provide: increased energy expenditure and direct hepatic fat clearance. This is a mechanistic rationale; clinical weight-loss results do not quantify how much each pathway contributes.

This is also what differentiates survodutide from retatrutide, which is a triple agonist targeting GLP-1, GIP, and glucagon. Survodutide omits GIP entirely, relying on the GLP-1/glucagon combination alone.

Clinical Trial Data

Phase 2 — Obesity (NCT04667377)

The published Phase 2 trial enrolled 387 adults without diabetes and tested four weekly doses for 46 weeks. Its planned-treatment analysis reported:
DoseAverage weight change at 46 weeks
0.6 mg−6.2%
2.4 mg−12.5%
3.6 mg−13.2%
4.8 mg−14.9%
Placebo−2.8%

The widely quoted 18.7% figure comes from a different analysis and should not replace the primary planned-treatment result. Neither analysis establishes superiority over semaglutide or another drug tested in a separate trial.

The later SYNCHRONIZE-1 Phase 3 publication reports 12.2% and 13.0% weight loss with 3.6 mg and 6.0 mg at 76 weeks, compared with 5.4% on placebo, using its treatment-regimen estimand.

Phase 2 — MASH (Liver Disease)

In the 48-week Phase 2 MASH trial, the primary endpoint was MASH improvement without worsening fibrosis, not MASH resolution. It occurred in 47%, 62% and 43% of participants assigned to 2.4 mg, 4.8 mg and 6.0 mg, respectively, versus 14% on placebo.

Fibrosis improved by at least one stage without worsening MASH in 34%, 36% and 34%, versus 22% with placebo. These endpoints measure different changes in a liver biopsy. The frequently quoted 83% figure reflects a different analysis and is not the primary randomized-dose result.

Survodutide Side Effects

Gastrointestinal adverse events are common. In SYNCHRONIZE-1, they occurred in 80.9% of participants on 3.6 mg, 89.7% on 6.0 mg and 47.9% on placebo. Nausea, vomiting and diarrhea are important tolerability considerations.

These results describe trial participants under monitoring. They do not establish that long-term risks are fully known or that survodutide is safer than another medicine.

How Survodutide Compares to Other Drugs

Survodutide targets GLP-1 and glucagon receptors. Semaglutide targets GLP-1; tirzepatide targets GLP-1 and GIP; retatrutide targets all three.

Weight-loss percentages from separate trials cannot rank these drugs reliably. Participants, treatment duration, dose escalation and handling of discontinued treatment differ. For survodutide, use the published Phase 3 result above rather than treating an earlier Phase 2 headline as the final estimate.

Liver-fat reduction, MASH improvement, MASH resolution and fibrosis improvement are also distinct endpoints. A receptor mechanism alone does not establish better liver outcomes.

Survodutide vs Retatrutide

Survodutide is a dual GLP-1/glucagon agonist; retatrutide adds GIP receptor activity. Separate trials cannot isolate whether GIP explains a difference in weight loss.
Our retatrutide vs survodutide article compares the evidence. It is not a report of a direct head-to-head trial.

Current Status and Availability

  • Developer: Boehringer Ingelheim (in partnership with Zealand Pharma)
  • Regulatory status: Not FDA approved. Not approved in any country.
  • Phase 3 trials: SYNCHRONIZE-1 obesity results published; MASH development continues
  • Commercial availability: Not available commercially. Cannot be prescribed or purchased.
  • Brand name: None assigned yet

Survodutide is currently only available to participants enrolled in clinical trials. There is no legitimate way to obtain survodutide outside of a clinical trial setting. Any online sources claiming to sell survodutide are unregulated and potentially dangerous.

Frequently Asked Questions

What is survodutide?

Survodutide (BI 456906) is an investigational dual GLP-1/glucagon receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. It is a once-weekly subcutaneous injection being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis). It is not FDA approved.

How much weight can you lose on survodutide?

In SYNCHRONIZE-1, adults without diabetes lost an average of 12.2% on 3.6 mg and 13.0% on 6.0 mg at 76 weeks, versus 5.4% on placebo, in the analysis accounting for treatment discontinuation. Individual outcomes vary.

What are survodutide's side effects?

Gastrointestinal events occurred in 80.9% and 89.7% of the two survodutide groups in SYNCHRONIZE-1, versus 47.9% with placebo. Nausea, vomiting and diarrhea are key concerns; longer-term safety remains under study.

Is survodutide FDA approved?

No. Survodutide is not FDA approved and is not approved in any country. It is currently in Phase 3 clinical trials for both obesity and MASH. There is no confirmed timeline for a regulatory submission.

How does survodutide help with liver disease (MASH)?

It is being studied for MASH. The Phase 2 primary endpoint was MASH improvement without worsening fibrosis: 47%, 62% and 43% across the three randomized doses, versus 14% with placebo at 48 weeks. This was not an 83% MASH-resolution result.

How does survodutide compare to retatrutide?

Survodutide targets GLP-1 and glucagon; retatrutide also targets GIP. There is no direct comparison in the trials summarized here, so their separate weight-loss results cannot establish superiority or explain which receptor caused a difference.

What doses of survodutide are being tested?

Phase 2 obesity research tested 0.6, 2.4, 3.6 and 4.8 mg weekly. The published Phase 3 SYNCHRONIZE-1 trial tested 3.6 and 6.0 mg weekly. These are study doses, not an approved prescribing schedule.

How is survodutide different from semaglutide and tirzepatide?

Survodutide targets GLP-1 and glucagon, semaglutide targets GLP-1, and tirzepatide targets GLP-1 and GIP. The glucagon component is part of the rationale for studying liver disease, but the receptor pairing alone does not prove better outcomes.

Sources

  1. Boehringer Ingelheim. "Survodutide Phase 2 obesity trial results." ClinicalTrials.gov (NCT04667377)
  2. Sanyal AJ, et al. Phase 2 survodutide MASH trial. Publication
  3. SYNCHRONIZE-1 Phase 3 obesity trial, 2026. NEJM
  4. Phase 2 obesity dose-finding trial. The Lancet Diabetes & Endocrinology
  5. Jastreboff AM, et al. "Retatrutide once weekly for treatment of obesity." New England Journal of Medicine. 2023. NEJM
  6. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity (STEP 1)." New England Journal of Medicine. 2021. NEJM
  7. Jastreboff AM, et al. "Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1)." New England Journal of Medicine. 2022. NEJM
This article is for informational purposes only and does not constitute medical advice. Survodutide is an investigational compound that has not been approved by the FDA or any regulatory authority. Always consult a healthcare provider before starting any medication.
How we keep this honest
What this is
Educational information, not medical advice. It reports published research — it doesn’t recommend that you use, obtain, or supply anything.
Regulatory status
Retatrutide and similar peptides are investigational — not approved by the FDA or any regulator. Semaglutide and tirzepatide are prescription-only medicines, available only through a licensed prescriber.
Our standard
Every claim traces to a primary source. We label the strength of evidence and flag estimates as estimates — never as clinical fact.
No commercial ties
We don’t sell, supply, or link to suppliers of any medicine, and aren’t affiliated with any manufacturer.

Do not make decisions about your health without consulting a qualified healthcare provider. For trial enrolment, see ClinicalTrials.gov. More on how we review.

Grounded in primary sources
NEJMThe LancetJAMAFDAClinicalTrials.gov

Keep exploring

Explore all drugs topics →